Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

NCT02469246 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

567

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: F/TAF
DRUG: ABC/3TC
DRUG: ABC/3TC Placebo
DRUG: F/TAF Placebo
DRUG: 3rd ARV agent

Sponsor

Gilead Sciences